[多原发性肺癌的治疗进展]
[Advances in the Treatment of Multiple Primary Lung Cancer].
作者信息
Xiao Ying, Chen Xiaobo, Tong Xinghe, Yang Xudong, Yang Yanlong, Zhao Yunping
机构信息
Department of Thoracic Surgery, The First Affiliated Hospital of Kunming Medical University, Kunming 650100, China.
出版信息
Zhongguo Fei Ai Za Zhi. 2025 Jun 20;28(6):460-466. doi: 10.3779/j.issn.1009-3419.2025.102.17.
Abstract
In recent years, the incidence of multiple primary lung cancer (MPLC) has been increasing, and it cannot be ignored in clinical practice. The treatment of MPLC is still controversial, but surgical treatment is recognized as the most important treatment. However, current studies have shown that the treatment of MPLC needs to develop multimodal treatment according to different patients. This review summarizes multiple treatment method for MPLC, including surgery, ablation, chemotherapy, radiotherapy, targeted therapy, and immunotherapy in order to enhance understanding of MPLC treatment. .
摘要
近年来，多原发性肺癌（MPLC）的发病率一直在上升，在临床实践中不容忽视。MPLC的治疗仍存在争议，但手术治疗被认为是最重要的治疗方法。然而，目前的研究表明，MPLC的治疗需要根据不同患者制定多模式治疗方案。本文综述了MPLC的多种治疗方法，包括手术、消融、化疗、放疗、靶向治疗和免疫治疗，以加深对MPLC治疗的理解。
相似文献
1
[Advances in the Treatment of Multiple Primary Lung Cancer].[多原发性肺癌的治疗进展]
Zhongguo Fei Ai Za Zhi. 2025 Jun 20;28(6):460-466. doi: 10.3779/j.issn.1009-3419.2025.102.17.
2
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
3
A systematic overview of chemotherapy effects in non-small cell lung cancer.非小细胞肺癌化疗效果的系统综述。
Acta Oncol. 2001;40(2-3):327-39. doi: 10.1080/02841860151116402.
4
The Black Book of Psychotropic Dosing and Monitoring.《精神药物剂量与监测黑皮书》
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.
5
The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.卡莫司汀植入剂与替莫唑胺治疗新诊断的高级别胶质瘤的有效性和成本效益：一项系统评价与经济学评估
Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. doi: 10.3310/hta11450.
6
Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.用于经手术或根治性放疗治疗的Ⅰ至Ⅲ期非小细胞肺癌的免疫疗法（不包括检查点抑制剂）。
Cochrane Database Syst Rev. 2017 Dec 16;12(12):CD011300. doi: 10.1002/14651858.CD011300.pub2.
7
A systematic overview of chemotherapy effects in acute myeloid leukaemia.急性髓系白血病化疗效果的系统综述。
Acta Oncol. 2001;40(2-3):231-52. doi: 10.1080/02841860151116321.
8
Assessing the comparative effects of interventions in COPD: a tutorial on network meta-analysis for clinicians.评估慢性阻塞性肺疾病干预措施的比较效果：面向临床医生的网状Meta分析教程
Respir Res. 2024 Dec 21;25(1):438. doi: 10.1186/s12931-024-03056-x.
9
A systematic overview of chemotherapy effects in B-cell chronic lymphocytic leukaemia.B 细胞慢性淋巴细胞白血病化疗效果的系统综述。
Acta Oncol. 2001;40(2-3):224-30. doi: 10.1080/02841860151116303.
10
Management of urinary stones by experts in stone disease (ESD 2025).结石病专家对尿路结石的管理（2025年结石病专家共识）
Arch Ital Urol Androl. 2025 Jun 30;97(2):14085. doi: 10.4081/aiua.2025.14085.
本文引用的文献
1
Microwave ablation after VATS in patients with multiple pulmonary nodules.电视辅助胸腔镜手术（VATS）后对多发肺结节患者进行微波消融治疗。
J Cancer Res Ther. 2024 Dec 1;20(7):2029-2034. doi: 10.4103/jcrt.jcrt_898_24. Epub 2024 Oct 15.
2
Stereotactic body radiotherapy with sequential tislelizumab and chemotherapy as neoadjuvant therapy in patients with resectable non-small-cell lung cancer in China (SACTION01): a single-arm, single-centre, phase 2 trial.在中国可切除非小细胞肺癌患者中序贯替雷利珠单抗与化疗作为新辅助治疗的立体定向体部放射治疗（SACTION01）：一项单臂、单中心的2期试验。
Lancet Respir Med. 2024 Dec;12(12):988-996. doi: 10.1016/S2213-2600(24)00215-7. Epub 2024 Sep 18.
3
EGFR plus MET Targeted Therapies for Overcoming Treatment Resistance in EGFR-Mutant Non-Small Cell Lung Cancer: A Case Report.
Oncol Res Treat. 2024;47(12):616-623. doi: 10.1159/000541496. Epub 2024 Sep 18.
4
[Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2024 edition)].《中国医学协会肺癌临床诊疗指南（2024年版）》
Zhonghua Zhong Liu Za Zhi. 2024 Sep 23;46(9):805-843. doi: 10.3760/cma.j.cn112152-20240510-00189.
5
MDT-BRIDGE: Neoadjuvant Durvalumab Plus Chemotherapy Followed by Either Surgery and Adjuvant Durvalumab or Chemoradiotherapy and Consolidation Durvalumab in Resectable or Borderline-resectable Stage IIB-IIIB NSCLC.MDT-BRIDGE：可切除或边缘可切除的 IIB-IIIB 期 NSCLC 患者中，新辅助度伐利尤单抗联合化疗，然后手术联合辅助度伐利尤单抗，或放化疗联合巩固性度伐利尤单抗。
Clin Lung Cancer. 2024 Sep;25(6):587-593.e3. doi: 10.1016/j.cllc.2024.06.007. Epub 2024 Jun 21.
6
Advances in the diagnosis and treatment of multiple primary lung cancers.多原发性肺癌的诊断与治疗进展
Asian J Surg. 2024 Jun;47(6):2635-2636. doi: 10.1016/j.asjsur.2024.03.022. Epub 2024 Mar 27.
7
[Chinese expert consensus on evaluation and treatment of advanced non-small cell lung cancer with negative driver genes after first-line immunotherapy resistance (2024 edition)].《一线免疫治疗耐药后驱动基因阴性晚期非小细胞肺癌评估与治疗中国专家共识（2024年版）》
Zhonghua Yi Xue Za Zhi. 2024 Feb 6;104(6):411-426. doi: 10.3760/cma.j.cn112137-20230927-00589.
8
Perioperative Immunotherapy in Non-Small Cell Lung Cancer.非小细胞肺癌的围手术期免疫治疗
Curr Treat Options Oncol. 2023 Dec;24(12):1790-1801. doi: 10.1007/s11864-023-01160-6. Epub 2023 Dec 13.
9
Neoadjuvant nivolumab with or without platinum-doublet chemotherapy based on PD-L1 expression in resectable NSCLC (CTONG1804): a multicenter open-label phase II study.基于 PD-L1 表达的可切除 NSCLC 患者新辅助纳武利尤单抗联合或不联合含铂双药化疗（CTONG1804）：一项多中心、开放标签、Ⅱ期研究。
Signal Transduct Target Ther. 2023 Dec 6;8(1):442. doi: 10.1038/s41392-023-01700-4.
10
Neoadjuvant therapy in non-small cell lung cancer.非小细胞肺癌的新辅助治疗
Crit Rev Oncol Hematol. 2023 Oct;190:104080. doi: 10.1016/j.critrevonc.2023.104080. Epub 2023 Aug 1.
Zotero 插件